📘 PATENTS ACT, 1970 — A COMPLETE DETAILED, SECTION-WISE BLOG WITH LANDMARK CASE BRIEFS

🔍 Introduction

The Patents Act, 1970 is the principal legislation governing patent laws in India, providing the framework for granting, protecting, and enforcing patents. The Act aims to encourage innovation by granting inventors exclusive rights over their inventions for a limited period.

This blog provides:

Section-wise explanation
Important provisions
Landmark Supreme Court & High Court cases
Case briefs
SEO-rich headings and keywords

📌 CHAPTER-WISE & SECTION-WISE ANALYSIS OF THE PATENTS ACT, 1970

📍 CHAPTER I – PRELIMINARY (Sections 1–2)

Section 2 – Key Definitions

Important terms include:

Invention – A new product or process involving inventive step and industrial applicability.
Inventive Step – A technical advance or economic significance.
New Invention – Not anticipated in prior art.

📍 CHAPTER II – INVENTIONS NOT PATENTABLE (Sections 3–5)

Section 3 – Non-Patentable Inventions

Important clauses:

Section 3(d) – New forms of known substances without enhanced efficacy are not patentable.
Section 3(c) – Natural discoveries are not patentable.
Section 3(i) – Medical, surgical, or curative processes.
Section 3(j) – Plants and animals except microorganisms.

Landmark Case: Novartis AG v. Union of India (2013)

Facts: Novartis sought patent for cancer drug Glivec.
Issue: Whether a new crystalline form of a known substance qualifies as an invention under Section 3(d).
Judgment: Supreme Court rejected the patent, holding that mere modifications without enhanced therapeutic efficacy are not patentable.
Legal Principle: Reinforced the strict interpretation of Section 3(d) to prevent evergreening of patents.

📍 CHAPTER III – APPLICATION FOR PATENTS (Sections 6–11)

Section 6 – Who Can Apply?

Inventor
Assignee
Legal representative

Section 10 – Contents of Complete Specification

Must include:

Description
Claims
Abstract
Drawings (if needed)

📍 CHAPTER IV – PUBLICATION & EXAMINATION (Sections 11A–21)

Section 11A – Publication of Applications

Published after 18 months, unless early publication is requested.

Section 12–15 – Examination

The controller examines:

Novelty
Inventive step
Industrial application
Patentability under Section 3

Section 18 – Amendments during Examination

📍 CHAPTER V – OPPOSITION PROCEEDINGS (Sections 25–28)

Section 25 – Opposition

Two types:

Pre-grant Opposition
Post-grant Opposition

Landmark Case: UCB Farchim SA v. Cipla Ltd. (2010)

Facts: Patent opposition filed for respiratory medicine.
Held: The IPAB emphasized that public interest is a priority in granting pharmaceutical patents.

📍 CHAPTER VI – ANTICIPATION (Sections 29–34)

Section 29 – Public Knowledge/Use

If an invention is publicly known or used, it is not patentable.

📍 CHAPTER VII – PROVISIONS FOR SECRECY (Sections 35–42)

Government may restrict publication of patents relevant to national security.

📍 CHAPTER VIII – GRANT & SEALING OF PATENTS (Sections 43–53)

Section 48 – Rights of Patentee

Exclusive right to:

Make
Use
Sell
Import the patented product

Section 53 – Term of Patent

20 years from the filing date.

📍 CHAPTER IX – PATENTS OF ADDITION (Sections 54–56)

Allows patenting of improvements or modifications to existing inventions.

📍 CHAPTER X – ASSIGNMENT & TRANSMISSION (Sections 68–72)

Patent rights can be:

Assigned
Licensed
Transferred

📍 CHAPTER XI – REVOCATION OF PATENTS (Sections 64–66)

Section 64 – Grounds for Revocation

Such as:

Wrongful obtaining
Lack of novelty
Non-patentability
Insufficient disclosure

Landmark Case: Enercon (India) Ltd. v. Enercon GmbH (2014)

Court strengthened technical expert involvement in patent disputes.

📍 CHAPTER XII – REGISTER OF PATENTS (Sections 67–77)

Maintained by Controller.

📍 CHAPTER XIII – PATENT AGENTS (Sections 125–132)

Patent agents must qualify the Patent Agent Examination.

📍 CHAPTER XIV – WORKING OF PATENTS, COMPULSORY LICENSING (Sections 82–94)

Section 84 – Compulsory Licensing

Can be granted if:

Reasonable requirements of public not met
Not affordable
Not worked in India

Landmark Case: Bayer Corporation v. Natco Pharma (2012)

Facts: Natco sought a compulsory license for cancer drug Nexavar.
Held: First compulsory license granted in India.
Principle: High prices and low availability justify compulsory licensing.

📍 CHAPTER XV – USE OF INVENTIONS FOR GOVERNMENT PURPOSES (Sections 99–106)

Enables government use in public interest.

📍 CHAPTER XVI – INFRINGEMENT (Sections 104–114)

Section 104 – Jurisdiction

High Court or notified commercial courts.

Section 108 – Reliefs in Suit for Infringement

Injunction
Damages
Accounts of profits
Destruction of infringing goods

Landmark Case: TVS Motor Co. v. Bajaj Auto Ltd. (2009)

Court addressed balancing innovation vs. competition in patent injunction matters.

📍 CHAPTER XVII – PATENT OFFENCES (Sections 118–124)

Includes penalties for:

Falsification
Misrepresentation
Wrongful use of words “patent”

📍 CHAPTER XVIII – MISCELLANEOUS (Sections 133–162)

Includes international arrangements, powers of the controller, etc.

📌 CONCLUSION

The Patents Act, 1970 is a crucial legal framework for fostering innovation in India. Through sections addressing patentability, specifications, compulsory licensing, and enforcement, the Act ensures a balance between inventor rights and public interest.

The landmark judgments—Novartis, Bayer v. Natco, Enercon, and others—continue to shape the interpretation of patent law in India.

PATENTS ACT, 1970 — A COMPLETE DETAILED, SECTION-WISE BLOG WITH LANDMARK CASE BRIEFS